Gilead CMO quits six months after taking job; Allergan taps Pfizer vet as CMO; and Novartis recruits Siemens ethics chief as it reels from scandal.

The imminent departure leaves Pfenex without a CMO as it gears up to file a new drug application (NDA), although Chen will continue to advise the biotech.

In our EuroBiotech roundup this week, Crescendo hits a milestone in its Takeda pact, Adaptimmune dials up dosing and A1M Pharma shifts its focus.

Biohaven’s new formulation of ALS drug riluzole has helped people with social anxiety face the challenge of speaking in public.

Fasinumab cleared the efficacy bar but triggered safety alarms, keeping it on the tail of Pfizer and Eli Lilly’s rival drug without dispelling doubts.

In this week's EuroBiotech Report, Pfizer, BioNTech ink $425 million deal, British biotechs reel in $247 million in VC cash and more.

Pfizer has also committed to up to $305 million in development, regulatory and commercial milestones to seal the deal.

Third Rock Ventures has named Steven Kafka, former president and chief operating officer of Foundation Medicine, as a new venture partner.

Blueberry Therapeutics raised £10 million in series B funding that will advance a nanomedicine for athlete's foot and a fungal nail infection.